Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for elective or urgent percutaneous coronary intervention~* Who are suitable candidates for either conventional angioplasty or primary intracoronary stent implantation~* Having a target artery (native or graft) stenosis of \>= 60% (visual estimation)~Exclusion Criteria:~* Patients with acute ST-segment elevation myocardial infarction within the previous 12 hours~* With a planned staged procedure or having an unprotected left main coronary artery stenosis \> 50%~* With active internal bleeding, having a condition that may increase the risk of bleeding, or receiving ongoing treatment with an oral anticoagulant at the time of study entry~* Having had a percutaneous coronary intervention within the previous 3 months or prior intracoronary stent placement in a target vessel~* Having hypertension with systolic blood pressure \> 180 mm Hg or diastolic blood pressure \> 100 mm Hg at the time of study entry, or a platelet count \< 100,000/μL at baseline

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angioplasty With Abciximab Plus Low-Dose Heparin (Type: EXPERIMENTAL): Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
- Intracoronary Stent With Reo Pro Plus Low Dose Heparin (Type: EXPERIMENTAL): Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
- Intracoronary Stent With Placebo Plus Standard Dose Heparin (Type: PLACEBO_COMPARATOR): Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).